Insulin aspart, recombinant Subcutaneous and Olaratumab Intravenous
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Olaratumab Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: olaratumab
Brand name: Lartruvo
Synonyms: Olaratumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Oleptro
- Insulin aspart, recombinant Subcutaneous-Oleptro Oral
- Insulin aspart, recombinant Subcutaneous-Olmesartan
- Insulin aspart, recombinant Subcutaneous-Olmesartan and Hydrochlorothiazide
- Insulin aspart, recombinant Subcutaneous-Olmesartan Medoxomil
- Insulin aspart, recombinant Subcutaneous-Olmesartan Medoxomil and Hydrochlorothiazide
- Olaratumab Intravenous-Insulin degludec
- Olaratumab Intravenous-Insulin Degludec (U-100) Prefilled Pens
- Olaratumab Intravenous-Insulin Degludec (U-100) Vials
- Olaratumab Intravenous-Insulin Degludec (U-200) Prefilled Pens
- Olaratumab Intravenous-Insulin degludec and liraglutide
- Olaratumab Intravenous-Insulin degludec and liraglutide Subcutaneous